1
|
Kerrouche O, Amghar H, Haddad H. [Sudden death in adults : Data from 305 consecutive autopsy cases in Algeria]. Ann Cardiol Angeiol (Paris) 2024; 73:101760. [PMID: 38761589 DOI: 10.1016/j.ancard.2024.101760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2023] [Revised: 03/22/2024] [Accepted: 03/27/2024] [Indexed: 05/20/2024]
Abstract
BACKGROUND-AIMS Sudden death in a young adult who showed no prodrome or complaint during his lifetime is a tragedy. The death often remains unexplained by doctors and is often the subject of a judicial investigation following which an autopsy is ordered. Our study joins several studies around the world, where the results have linked sudden death in adults to a cardiac origin. METHODS Through a series of 305 autopsies carried out in the forensic medicine department of the Frantz Fanon hospital in the city of Bejaia in Algeria over a period of two years, 57 cases corresponded to unexplained sudden deaths, i.e. an incidence of 3 cases per 100,000 inhabitants per year. RESULTS Sudden death was of cardiac origin in 50.8% of cases (N=28). Two epidemiologic profiles emerge in our study: the first is that of a man aged between 50 and 60 years of age, with several deleterious lifestyle habits (in particular smoking) with a cardiovascular history, previously followed by a cardiologist, who died suddenly out-of-hospital, from ischemic heart disease. The second is that of a young adult under 40 years of age, of average build, with no particular medical history, having not previously consulted a cardiologist, who died suddenly of hypertrophic cardiomyopathy. CONCLUSIONS In many instances, we observed major anatomical lesion, which had not motivated any prior medical consultation either with a general practitioner or with a cardiologist.
Collapse
Affiliation(s)
- Oussama Kerrouche
- Enseignant chercheur hospitalo-universitaire à la faculté de médecine, université de Tlemcen, Algérie; Maitre-assistant en médecine légale, droit médical et éthique de santé, service de médecine légale du CHU de Tlemcen, Algérie.
| | - Houssam Amghar
- Assistant praticien en anesthésie et réanimation à l'établissement public hospitalier d'Ain Salah, Algérie; Enseignant chercheur hospitalo-universitaire à la faculté de médecine, université de Tlemcen, Algérie
| | - Hicham Haddad
- Assistant praticien en anesthésie et réanimation à l'établissement public hospitalier d'Ain Bessam, Bouira, Algérie; Maitre-assistant en médecine légale, droit médical et éthique de santé, service de médecine légale du CHU de Tlemcen, Algérie
| |
Collapse
|
2
|
Montani D, Eichstaedt CA, Belge C, Chung WK, Gräf S, Grünig E, Humbert M, Quarck R, Tenorio-Castano JA, Soubrier F, Trembath RC, Morrell NW. [Genetic counselling and testing in pulmonary arterial hypertension - A consensus statement on behalf of the International Consortium for Genetic Studies in PAH - French version]. Rev Mal Respir 2023; 40:838-852. [PMID: 37923650 DOI: 10.1016/j.rmr.2023.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Accepted: 08/11/2023] [Indexed: 11/07/2023]
Abstract
Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by (likely) pathogenic germline genomic variants. In addition to the most prevalent disease gene, BMPR2 (bone morphogenetic protein receptor 2), several genes, some belonging to distinct functional classes, are also now known to predispose to the development of PAH. As a consequence, specialist and non-specialist clinicians and healthcare professionals are increasingly faced with a range of questions regarding the need for, approaches to and benefits/risks of genetic testing for PAH patients and/or related family members. We provide a consensus-based approach to recommendations for genetic counselling and assessment of current best practice for disease gene testing. We provide a framework and the type of information to be provided to patients and relatives through the process of genetic counselling, and describe the presently known disease causal genes to be analysed. Benefits of including molecular genetic testing within the management protocol of patients with PAH include the identification of individuals misclassified by other diagnostic approaches, the optimisation of phenotypic characterisation for aggregation of outcome data, including in clinical trials, and importantly through cascade screening, the detection of healthy causal variant carriers, to whom regular assessment should be offered.
Collapse
Affiliation(s)
- D Montani
- French Referral Center for Pulmonary Hypertension, Pulmonary Department, hôpital de Bicêtre, AP-HP, université Paris-Saclay, Le Kremlin-Bicêtre, France; Inserm UMR_S999, hôpital Marie-Lannelongue, Le Plessis-Robinson, France.
| | - C A Eichstaedt
- Center for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Heidelberg, Allemagne; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Allemagne; Laboratory for Molecular Diagnostics, Institute of Human Genetics, Heidelberg University, Heidelberg, Allemagne
| | - C Belge
- Department of Chronic Diseases & Metabolism (CHROMETA), Clinical Department of Respiratory Diseases, University Hospitals, Laboratory of Respiratory Diseases & Thoracic Surgery (BREATHE), University of Leuven, 3000 Leuven, Belgique
| | - W K Chung
- Department of Pediatrics, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, États-Unis
| | - S Gräf
- Department of Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge CB2 0BB, Royaume-Uni; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0PT, Royaume-Uni; NIHR BioResource, for Translational Research - Rare Diseases, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, Royaume-Uni
| | - E Grünig
- Center for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Heidelberg, Allemagne; Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Allemagne
| | - M Humbert
- French Referral Center for Pulmonary Hypertension, Pulmonary Department, hôpital de Bicêtre, AP-HP, université Paris-Saclay, Le Kremlin-Bicêtre, France; Inserm UMR_S999, hôpital Marie-Lannelongue, Le Plessis-Robinson, France
| | - R Quarck
- Department of Chronic Diseases & Metabolism (CHROMETA), Clinical Department of Respiratory Diseases, University Hospitals, Laboratory of Respiratory Diseases & Thoracic Surgery (BREATHE), University of Leuven, 3000 Leuven, Belgique
| | - J A Tenorio-Castano
- INGEMM, Instituto de Genética Médica y Molecular, IdiPAZ, Hospital Universitario La Paz, Madrid, Espagne; CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Espagne; ITHACA, European Reference Network, Brussels, Belgique
| | - F Soubrier
- Département de génétique, Inserm UMR_S1166, AP-HP, hôpital Pitié-Salpêtrière, Institute for Cardio-metabolism and Nutrition (ICAN), Sorbonne université, Paris, France
| | - R C Trembath
- Department of Medical & Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London SE1 9RT, Royaume-Uni
| | - N W Morrell
- Department of Medicine, University of Cambridge, Heart and Lung Research Institute, Cambridge Biomedical Campus, Cambridge CB2 0BB, Royaume-Uni; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0PT, Royaume-Uni
| |
Collapse
|
3
|
Réguerre Y, Golmard L, Brisse HJ, Oliver Petit I, Savagner F, Boudjemaa S, Gauthier-Villars M, Rod J, Fresneau B, Orbach D. [DICER1 constitutional pathogenic variant syndrome: Where are we in 2019?]. Bull Cancer 2019; 106:1177-1189. [PMID: 31610911 DOI: 10.1016/j.bulcan.2019.08.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Revised: 08/09/2019] [Accepted: 08/14/2019] [Indexed: 11/30/2022]
Abstract
Inactivating germline pathogenic variants of the DICER1 gene are responsible for a spectrum of rare diseases, which expanded a lot in recent years. The constitution of an U.S. registry with these patients and their families as well as the registration of patients in European databases of rare tumors helped to better identify diseases encountered in this syndrome but also to study its pathophysiology (major role in miRNA maturation and recently discovered functions, e.g. in genome integrity maintenance). Most encountered disorders are pediatric malignancies, mainly the pulmonary pneumoblastoma and Sertoli-Leydig tumours. However, benign pathologies such as thyroid goiters, cystic nephromas or pulmonary cystic lesions are also frequently reported. Homogeneous guidelines regimens written by the European groups working on very rare pediatric tumors are proposed but it is important to underscore that they rely on rare scientific data; therefore overall consensus remains precarious. The genetic counseling to families is still difficult due to the large observed spectrum of tumors and the incomplete penetrance. In this article, the authors update current knowledge on the DICER1 syndrome.
Collapse
Affiliation(s)
- Yves Réguerre
- Centre Hospitalo-Universitaire de Saint Denis, service d'oncologie et d'hématologie pédiatrique, 97400 La Réunion, France.
| | - Lisa Golmard
- Institut Curie, service de génétique, 75005 Paris, France
| | - Hervé J Brisse
- Institut Curie, université Paris Sciences et Lettres, département d'imagerie, 26, rue d'Ulm Paris, 75005 Paris, France
| | - Isabelle Oliver Petit
- Hôpital des enfants, unité d'endocrinologie, génétique, maladies osseuses et gynécologie de l'enfant, TSA 70034, 31059 Toulouse Cedex, France
| | - Frédérique Savagner
- Hôpital Purpan, biologie moléculaire endocrinienne, service de biochimie, IFB, TSA 40031, 31059 Toulouse cedex, France
| | - Sabah Boudjemaa
- Hôpital d'enfants Armand Trousseau-assistance publique, service d'anatomie et de cytologie pathologiques, 75012 Paris, France
| | | | - Julien Rod
- Université de Caen, département de chirurgie pédiatrique, 14000 Caen, France; Université de Caen Basse-Normandie, UFR Médecine, 14000 Caen, France
| | - Brice Fresneau
- Université Paris-Saclay, Gustave Roussy, département d'oncologie pédiatrique, 94805 Villejuif, France; Inserm, université Paris-Sud Paris-Saclay, CESP, 94805 Villejuif, France
| | - Daniel Orbach
- Institut Curie, PSL université, Centre oncologie SIREDO (Soins, innovation recherche en oncologie de l'enfant, l'adolescent et du jeune adulte), 75005 Paris, France
| |
Collapse
|
4
|
Morice-Picard F. [Genetics and dermatology]. Ann Dermatol Venereol 2019; 146:326-339. [PMID: 31006539 DOI: 10.1016/j.annder.2019.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Many types of genodermatosis exist, with numerous modes of transmission. The development of molecular genetic methods, in particular the most recent sequencing techniques, can be used to identify an increasing number of genes involved in these forms of genodermatosis while providing confirmation or more details regarding clinical diagnosis. Thanks to this approach, it is possible to determine risk of recurrence and to formulate an antenatal strategy. These technologies have led to improved molecular definition and to a better understanding of the physiopathological mechanisms involved in different genodermatoses such as bullous epidermolysis, keratinisation disorders, pigmentation disorders, potentially tumoral conditions, and epidermal and pilar dysplasia. The large amount of information provided by high-throughput sequencing makes it possible to study modifying genes as well as genotype-phenotype correlations. However, this genetic information in its turn poses problems of interpretation and of control of the resulting data. The use of genetics in dermatology for the purposes of diagnosis or research requires a consultation to provide patients with information regarding the genetic tests involved and the potential consequences thereof for them and their families. Furthermore, with pangenomic approaches there is a higher probability of fortuitous discovery of abnormalities such as variants associated with risks predisposing to cancer or neurodegenerative disease. Collaboration between dermatologists and geneticists enables optimisation of patient management in terms of diagnosis and genetic counselling in the event of such rare diseases. Therapeutic applications are beginning to be developed. The scope of therapeutic application includes gene therapy, replacement therapy (enzyme therapy) and targeted therapy.
Collapse
Affiliation(s)
- F Morice-Picard
- Service de dermatologie pédiatrique et dermatologie, Centre de référence des maladies rares de la peau, Hôpital pédiatrique, Groupe hospitalier Pellegrin, Centre hospitalier universitaire de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
| |
Collapse
|
5
|
Moretta J, Berthet P, Bonadona V, Caron O, Cohen-Haguenauer O, Colas C, Corsini C, Cusin V, De Pauw A, Delnatte C, Dussart S, Jamain C, Longy M, Luporsi E, Maugard C, Nguyen TD, Pujol P, Vaur D, Andrieu N, Lasset C, Noguès C. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition]. Bull Cancer 2018; 105:907-917. [PMID: 30268633 DOI: 10.1016/j.bulcan.2018.08.003] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Revised: 08/03/2018] [Accepted: 08/06/2018] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Next generation sequencing allows the simultaneous analysis of large panel of genes for families or individuals with a strong suspicion of hereditary breast and/or ovarian cancer (HBOC). Because of lack of guidelines, several panels of genes potentially involved in HBOC were designed, with large disparities not only in their composition but also in medical care offered to mutation carriers. Then, homogenization in practices is needed. METHODS The French Genetic and Cancer Group (GGC) - Unicancer conducted an exhaustive bibliographic work on 18 genes of interest. Only publications with unbiased risk estimates were retained. RESULTS The expertise of each 18 genes was based on clinical utility criteria, i.e. a relative risk of cancer of 4 and more, available medical tools for screening and prevention of mutation carriers, and pre-symptomatic genetic tests for relatives. Finally, 13 genes were selected to be included in a HBOC diagnosis gene panel: BRCA1, BRCA2, PALB2, TP53, CDH1, PTEN, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, EPCAM. The reasons for excluding NBN, RAD51B, CHEK2, STK11, ATM, BARD1, BRIP1 from the HBOC diagnosis panel are presented. Screening, prevention and genetic counselling guidelines were detailed for each of the 18 genes. DISCUSSION Due to the rapid increase in knowledge, the GGC has planned a yearly update of the bibliography to take into account new findings. Furthermore, genetic-epidemiological studies are being initiated to better estimate the cancer risk associated with genes which are not yet included in the HBOC diagnosis panel.
Collapse
Affiliation(s)
- Jessica Moretta
- Institut Paoli-Calmettes, oncogénétique clinique, département d'anticipation et de suivi des cancers, 232, boulevard Sainte-Marguerite, 13009 Marseille, France.
| | - Pascaline Berthet
- Centre François-Baclesse, oncogénétique clinique, département de biopathologie, 14000 Caen, France
| | - Valérie Bonadona
- Centre Léon-Berard, unité clinique d'oncologie génétique, 69008 Lyon, France; Université Lyon 1, CNRS, LBBE UMR 5558, 69622 Villeurbanne, France
| | - Olivier Caron
- Gustave-Roussy hôpital universitaire, département de médecine, 94800 Villejuif, France
| | | | | | - Carole Corsini
- CHRU de Montpellier, hôpital Arnaud de Villeneuve, service d'oncogénétique, 34090 Montpellier, France
| | - Véronica Cusin
- Hôpital Pitié-Salpêtrière-Charles-Foix, service de génétique, 75013 Paris, France
| | | | - Capucine Delnatte
- ICO-Centre René-Gauducheau, unité d'oncogénétique, 44800 Nantes, France
| | - Sophie Dussart
- Centre Léon-Berard, unité clinique d'oncologie génétique, 69008 Lyon, France
| | | | - Michel Longy
- Institut Bergonié, oncogénétique, Inserm U 1218, 33000 Bordeaux, France
| | | | - Christine Maugard
- CHU de Strasbourg, oncogénétique clinique, oncogénétique moléculaire, évaluation familiale et suivi, laboratoire d'oncobiologie, 67000 Strasbourg, France
| | - Tan Dat Nguyen
- Institut Jean-Godinot, oncogénétique, 51100 Reims, France
| | - Pascal Pujol
- CHRU de Montpellier, hôpital Arnaud de Villeneuve, service d'oncogénétique, 34090 Montpellier, France
| | - Dominique Vaur
- Centre François-Baclesse, laboratoire de biologie et de génétique du cancer, 14000 Caen, France
| | - Nadine Andrieu
- Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, 75005 Paris, France
| | - Christine Lasset
- Université Lyon 1, CNRS, LBBE UMR 5558, 69622 Villeurbanne, France; Centre Léon Bérard, département de santé publique, unité de prévention et épidémiologie génétique, 69008 Lyon, France
| | - Catherine Noguès
- Institut Paoli-Calmettes, oncogénétique clinique, département d'anticipation et de suivi des cancers, 232, boulevard Sainte-Marguerite, 13009 Marseille, France; Aix-Marseille université, Inserm, IRD, SESSTIM, 13000 Marseille, France
| | | |
Collapse
|
6
|
Boufettal H, Quessar A, Jeddaoui Z, Mahdoui S, Noun M, Hermas S, Samouh N. [Pregnancy in Gaucher disease]. ACTA ACUST UNITED AC 2013; 43:397-400. [PMID: 23578492 DOI: 10.1016/j.jgyn.2012.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2012] [Revised: 10/30/2012] [Accepted: 11/21/2012] [Indexed: 11/28/2022]
Abstract
Gaucher disease is a lysosomal storage disorder due to deficiency of glucocerebrosidase. The association with pregnancy exposes the worsening of the disease and complications of pregnancy and puerperium. We report a case of pregnancy in a woman of 35 years, suffering from Gaucher disease type 1. Pregnancy had a favorable outcome. Complications occurred. They were kept under control. The outcome was favorable. The authors discuss the evolution of the disease during pregnancy and management of complications. They can occur during pregnancy, post-partum and breastfeeding. Support begins with preconception consultation. It involves finding and correcting the biological problems and deficiencies, and management of complications. Genetic counseling is important, it helps prevent inbreeding.
Collapse
Affiliation(s)
- H Boufettal
- Service de gynécologie-obstétrique, faculté de médecine et de pharmacie, université Ain Chok, centre hospitalier universitaire Ibn Rochd, Casablanca, Maroc.
| | - A Quessar
- Service d'hématologie et d'oncologie pédiatrique, faculté de médecine et de pharmacie, université Ain Chok, hôpital du 20-Août, centre hospitalier universitaire Ibn Rochd, Casablanca, Maroc
| | - Z Jeddaoui
- Service de gynécologie-obstétrique, faculté de médecine et de pharmacie, université Ain Chok, centre hospitalier universitaire Ibn Rochd, Casablanca, Maroc
| | - S Mahdoui
- Service de gynécologie-obstétrique, faculté de médecine et de pharmacie, université Ain Chok, centre hospitalier universitaire Ibn Rochd, Casablanca, Maroc
| | - M Noun
- Service de gynécologie-obstétrique, faculté de médecine et de pharmacie, université Ain Chok, centre hospitalier universitaire Ibn Rochd, Casablanca, Maroc
| | - S Hermas
- Service de gynécologie-obstétrique, faculté de médecine et de pharmacie, université Ain Chok, centre hospitalier universitaire Ibn Rochd, Casablanca, Maroc
| | - N Samouh
- Service de gynécologie-obstétrique, faculté de médecine et de pharmacie, université Ain Chok, centre hospitalier universitaire Ibn Rochd, Casablanca, Maroc
| |
Collapse
|
7
|
Abbo O, Vaysse F, Bieth E, Galinier P. [Van der Woude syndrome: An unrecognised clinical entity]. ANN CHIR PLAST ESTH 2014; 59:81-4. [PMID: 22014507 DOI: 10.1016/j.anplas.2011.09.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2011] [Accepted: 09/18/2011] [Indexed: 11/20/2022]
Abstract
Van der Woude syndrome is known to be the first syndromic cause of oral cleft. Apart clefts the cardinal signs are lower lip pits and hypodontia. IRF6 gene mutations have been recently identified as potential cause in this syndrome which permits to better understand its phenotype heterogeneity. Based on a literature review, we tried to cover the different aspects of this syndrome with an emphasis on genetic counselling and surgical correction of lip pits.
Collapse
|